Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma

Bookmark and Share
Published: 15 Jun 2019
Views: 1118
Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Dr Mark Roschewski presents results at the 2019 European Hematology Association (EHA) Annual Meeting from a study looking at the novel immunotherapy 5F9 plus rituximab which blocks CD47, a key macrophage/cancer checkpoint.

The 100 patients studied with the treatment were well tolerated and showed good durability.